In this article, we will list the 5 Best 52-Week High US Stocks to Buy. Please visit 10 Best 52-Week High US Stocks to Buy if you would like to see the extended list and the methodology behind it.
5. Vaxcyte Inc (NASDAQ:PCVX)
Stock Price as of April 21: $61.91
52-Week Range: $28.09 -$65.00
Stock Upside Potential: 80.24%
Number of Hedge Fund Holders: 46
Vaxcyte Inc (NASDAQ:PCVX) is among the best 52-week high US stocks to buy. Vaxcyte Inc (NASDAQ:PCVX) has completed enrollment in a pair of Phase 3 clinical trials evaluating its vaccine candidate VAX-31. The company announced this development on March 23, stating that it enrolled approximately 4,000 participants in the OPUS-1 trial and 1,300 in the OPUS-2 trial.
Vaxcyte’s vaccine candidate VAX-31 is intended to prevent invasive pneumococcal disease and pneumonia in adults. It’s also being tested in infants. The two Phase 3 trials that have completed enrollment are focused on adults.
In the OPUS-1 trial, VAX-31’s safety, tolerability, and immune response will be evaluated against two current standard pneumococcal vaccines. This study has two cohorts. It includes adults aged 50 years and older, and a separate group of adults aged 18 – 49 years. This study is being conducted at around 50 sites across the US, and its topline results are expected in Q4 2026.
The OPUS-2 trial will also evaluate the safety, tolerability, and immune response of VAX-31 in adults aged 50 and older. But in this study, they are assessing VAX-31 when administered alongside a licensed seasonal influenza vaccine. This is meant to be a descriptive study, and Vaxcyte said the results will inform a potential post-licensure outcomes study. The company is running the OPUS-2 trial at 25 sites across the US, and results are expected out in the first half of 2027.
At the end of 2025, Vaxcyte had $2.4 billion in cash. Then on February 24, the management disclosed that they had raised an additional $600 million in cash through equity financing to strengthen the company’s balance sheet and extend its cash runway.
Vaxcyte Inc (NASDAQ:PCVX), based in California, is a biotech company focused on developing advanced vaccines. It aims to offer solutions to prevent or treat bacterial diseases such as pneumonia. The company has several potential drugs in various development stages, with its most advanced drug candidates in Phase 3 trial stage.
4. Dianthus Therapeutics Inc (NASDAQ:DNTH)
Stock Price as of April 21: $91.42
52-Week Range: $16.64 – $96.50
Stock Upside Potential: 34.20%
Number of Hedge Fund Holders: 52
Dianthus Therapeutics Inc (NASDAQ:DNTH) is among the best 52-week high US stocks to buy. On March 26, William Blair reaffirmed an Outperform rating on Dianthus Therapeutics Inc (NASDAQ:DNTH) stock. This action followed an FDA update on safety requirements for Dianthus Therapeutics’ claseprubart clinical trials.
In the safety update, the FDA has dropped antinuclear antibodies as screening criterion. Also, the regulator has removed the requirement for routine ANA testing during claseprubart clinical trials. These changes make it easier for Dianthus Therapeutics to enroll patients and run the trials.
Notably, Dianthus can now enroll patients into the claseprubart studies without screening and removing participants for ANAs. According to William Blair, the FDA decision may have a positive impact on the potential drug’s labeling.
The firm noted that the CAPTIVATE trial interim responder analysis met its best-case scenario. As a result, William Blair believes claseprubart has a differentiated product profile.
Claseprubart is being developed as a potential therapy for various autoimmune disorders in areas with unmet needs. Dianthus Therapeutics plans to initiate a Phase 3 trial of claseprubart in patients with gMG in mid-2026. It expects topline results from this study in the second half of 2028.
A Phase 2 trial of claseprubart in patients with MMN is ongoing, with topline results expected in the second half of 2026. Also, the company expects to provide an update on topline guidance for Part B of the CAPTIVATE trial by the end of 2026.
Dianthus Therapeutics Inc (NASDAQ:DNTH) is an American biotech company focused on developing best-in-class antibody therapeutics. Its work is focused on therapies for patients living with severe autoimmune diseases to address unmet medical needs.
3. Xenon Pharmaceuticals Inc (NASDAQ:XENE)
Stock Price as of April 21: $56.48
52-Week Range: $28.19 – $63.95
Stock Upside Potential: 27.01%
Number of Hedge Fund Holders: 55
Xenon Pharmaceuticals Inc (NASDAQ:XENE) is among the best 52-week high US stocks to buy. On April 19, Xenon Pharmaceuticals Inc (NASDAQ:XENE) presented data from the Phase 3 X-TOLE2 study of its epilepsy drug candidate, azetukalner, at the American Academy of Neurology Annual Meeting in Chicago.
Xenon used the event to highlight the study’s strong results. It also used the platform to talk about its plans to seek regulatory approval for azetukalner.
In the late-stage study, patients treated with azetukalner showed a 53.2% reduction in monthly seizure frequency at the 25 mg dose. At the 15 mg dose, the monthly seizure frequency reduced by 34.5%. Those in the placebo group showed a 10.4% reduction.
Some patients achieved complete seizure control. Xenon revealed that the rate of 100% seizure reduction increased over time as patients remained in the therapy. In the final four weeks of the trial, 13.7% of patients in the 25 mg group and 12.8% of those in the 15 mg group achieved complete seizure control. That compared to 4.0% for the placebo group.
The study enrolled patients with treatment-resistant epilepsy who had around 12.75 seizures per month and had tried around five anti-seizure medications before.
Xenon plans to file for FDA approval of azetukalner in Q3 2026, with a decision expected in late 2027 or early 2028. On March 9, Reuters reported that analysts were estimating over $2 billion in peak sales for azetukalner if approved.
Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders, including epilepsy and depression. It has several potential drug products in the pipeline. The company is based in Canada, but it also has offices in the US.
2. Terawulf Inc (NASDAQ:WULF)
Stock Price as of April 21: $20.53
52-Week Range: $2.65 – $20.98
Stock Upside Potential: 39.82%
Number of Hedge Fund Holders: 62
Terawulf Inc (NASDAQ:WULF) is among the best 52-week high US stocks to buy. On April 16, Keefe, Bruyette & Woods reaffirmed its Outperform rating and $23 price target on Terawulf Inc (NASDAQ:WULF) stock. This action followed Terawulf’s equity offering to raise funds for projects and potential acquisitions. The company said it raised around $900 million in gross proceeds after issuing 47.4 million shares at $19.00 apiece. It upsized the offering from an initial target to raise $800 million.
Keefe views this equity raise by Terawulf as net positive. Terawulf said that it plans to use the proceeds from the offering to fund the construction of its planned data center campus in Hawesville, Kentucky. This would include the repayment of outstanding amounts under its bridge credit facility. Moreover, the company intends to use the funds for future site acquisitions and for general corporate purposes.
According to Keefe, the capital raise pre-funds the Hawesville data center project and removes uncertainty around post-leasing financing. The firm also noted the timing of the equity offering, pointing out that it comes as the stock trades close to its 52-week high, which indicates strong investor confidence.
Terawulf released its preliminary Q1 2026 results on April 14. The report revenue is expected in the range of $30 million to $35 million, and adjusted EBITDA is expected in the band of $0 million to $3 million. Terawulf closed Q1 with $3.1 billion in cash and $5.8 billion in debt.
Terawulf Inc (NASDAQ:WULF) is an American digital infrastructure company. It builds and operates industrial-scale data centers designed for high-performance computing hosting, AI workloads, and bitcoin mining. It specializes in providing low-carbon compute capacity.
1. ASML Holding NV (NASDAQ:ASML)
Stock Price as of April 21: €1,480.17
52-Week Range: €651.46 – €1,547.22
Stock Upside Potential: 20.43%
Number of Hedge Fund Holders: 101
ASML Holding NV (NASDAQ:ASML) is among the best 52-week high US stocks to buy. On April 16, Goldman Sachs increased its price target on ASML Holding NV (NASDAQ:ASML) to €1,570 from €1,450 while reiterating a Buy rating on the stock. For this action, Goldman Sachs pointed to the company’s strong Q1 2026 results and upbeat full-year 2026 outlook.
ASML released its Q1 results on April 15. The report showed net sales were €8.77 billion, above the consensus estimate of €8.5 billion. Net income of €2.76 billion also surpassed the consensus expectation of €2.54 billion.
The company boosted its full-year 2026 net sales projection to a range of €36 billion to €40 billion. The prior forecast called for net sales of €34 billion to €39 billion. ASML expects its 2026 gross margin to be between 51% and 53%. ASML supplies machines used for producing chips, including advanced chips for AI workloads.
In light of ASML’s Q1 results and 2026 guidance, Goldman Sachs raised its 2026-2030 revenue estimates for the company by 6% to 10%. Moreover, the investment bank boosted its gross profit estimates for ASML for the 2026-2030 period by 6% to 10%.
According to Goldman Sachs, ASML stands to benefit from continued strong demand for advanced chips and memory to power AI systems and other high-performance computing needs.
ASML Holding NV (NASDAQ:ASML) is a Dutch company that provides machines for manufacturing semiconductor chips. It supplies these machines to the world’s leading chipmakers like Intel, TSM, and Samsung. ASML’s manufacturing technology makes it possible to produce smaller chips at a faster rate and more efficiently.
While we acknowledge the potential of ASML to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ASML and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 9 Must-Buy Penny Stocks to Invest In Now and 10 Best AI Stocks to Buy Under $25.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
Hedge Fund Resource Center